ORIC Pharmaceuticals: Funding, Investors & Team (Oct 2026)
Our Story ORIC Pharmaceuticals is a clinical stage biopharmaceutical company dedicated to improving patients’ lives by Overcoming Resistance In Cancer. ORIC’s clinical stage product candidates include (1) ORIC-533, an orally bioavailable small molecule inhibitor of CD73, a key node in the adenosine pathway believed to play a central role in resistance to chemotherapy- and immunotherapy-based treatment regimens, being developed for multiple myeloma, (2) ORIC-114, a brain penetrant inhibitor designed to selectively target EGFR and HER2 with high potency against exon 20 insertion mutations, being developed across multiple genetically defined cancers, and (3) ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 (PRC2) via the EED subunit, being developed for prostate cancer. Beyond these three product candidates, ORIC is also developing multiple precision medicines targeting other hallmark cancer resistance mechanisms. ORIC has offices in South San Francisco and San Diego, California. For more information, please go to www.oricpharma.com, and follow us on Twitter or LinkedIn.
ORIC Pharmaceuticals has raised $110M across 2 funding rounds on record, the most recent an undisclosed round of $85.0M announced in Jun 2023.
That round is above the $8.1M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
ORIC Pharmaceuticals Company Profile and Key Stats
Latest funding round on record: Jun 2023.
ORIC Pharmaceuticals Funding Rounds
ORIC Pharmaceuticals raised $25.0M in an undisclosed round announced in Dec 2022.
6 months later, an undisclosed round of $85.0M was announced in Jun 2023.
ORIC Pharmaceuticals Founders and Leadership Team
Contact details for the ORIC Pharmaceuticals team: 2 of 2 have an email address on file.
Start 14-day free trial →ORIC Pharmaceuticals Funding Compared to Other Biotechnology Startups
ORIC Pharmaceuticals' latest round of $85.0M is above the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like ORIC Pharmaceuticals in Biotechnology and South San Francisco
Companies Similar to ORIC Pharmaceuticals
Kallyope, we believe that the gut is the gateway to our internal world. Containing millions of neurons, the…
Astrocyte Pharmaceuticals is a drug development company that helps in the recovery and well-being of brain…
Tiny Health offers a gut health test specifically designed for mothers and babies aged 0 to 3 years.…
Junevity is dedicated to using cutting-edge transcription factor medicines to combat age-related diseases.…
Arkea Bio creates technology aimed at reducing greenhouse gas (GHG) emissions in the agricultural sector.
Serán is a contract development and manufacturing organization providing a comprehensive suite of…
Precision’s goal is to provide breakthrough treatments for the one billion patients worldwide suffering from…
Enveda is a biotechnology company that utilizes AI-powered tools to explore and characterize molecules from…
Avery Therapeutics, Inc. is a company dedicated to developing tissue engineered therapeutics to treat…
Circle Pharma is a biotechnology company in the initial stages of development that uses unique computational…
Evvy is for people with vaginas who want to be empowered with information about their microbiome. Their…
ORIC Pharmaceuticals Funding FAQs
What does ORIC Pharmaceuticals do?
Our Story ORIC Pharmaceuticals is a clinical stage biopharmaceutical company dedicated to improving patients’ lives by Overcoming Resistance In Cancer. ORIC’s clinical stage product candidates include (1) ORIC-533, an orally bioavailable small molecule inhibitor of CD73, a key node in the adenosine pathway believed to play a central role in resistance to chemotherapy- and immunotherapy-based treatment regimens, being developed for multiple myeloma, (2) ORIC-114, a brain penetrant inhibitor designed to selectively target EGFR and HER2 with high potency against exon 20 insertion mutations, being developed across multiple genetically defined cancers, and (3) ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 (PRC2) via the EED subunit, being developed for prostate cancer. Beyond these three product candidates, ORIC is also developing multiple precision medicines targeting other hallmark cancer resistance mechanisms. ORIC has offices in South San Francisco and San Diego, California. For more information, please go to www.oricpharma.com, and follow us on Twitter or LinkedIn.
How much funding has ORIC Pharmaceuticals raised?
ORIC Pharmaceuticals has raised $110M across 2 rounds on record. The most recent is an undisclosed round of $85.0M announced in Jun 2023.
When did ORIC Pharmaceuticals last raise funding?
ORIC Pharmaceuticals' most recent funding round on record is an undisclosed round of $85.0M, announced in Jun 2023.
Who founded ORIC Pharmaceuticals?
FundedIQ lists Christian Kuhlen (Founder) at ORIC Pharmaceuticals.
Who is the CEO of ORIC Pharmaceuticals?
Jacob Chacko is listed as CEO at ORIC Pharmaceuticals.
Where is ORIC Pharmaceuticals headquartered?
ORIC Pharmaceuticals is based in South San Francisco, California, United States.
How many employees does ORIC Pharmaceuticals have?
ORIC Pharmaceuticals is in the 101-250 employee band.
How does ORIC Pharmaceuticals' funding compare to other Biotechnology startups?
ORIC Pharmaceuticals' latest round of $85.0M is above the $8.1M median round size for Biotechnology companies on FundedIQ across 4,185 tracked companies over the last two years.
About FundedIQ's ORIC Pharmaceuticals Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for ORIC Pharmaceuticals is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Startup funding intelligence on every funded startup: the round, the investors and the founders, as a file in your inbox or searchable in the app.
Radar from $49/mo · Pro from $149/mo. Card required, nothing charged until day 15, and we email you 3 days before that. Need something specific? Custom plans from $499/mo.